Antiviral therapy for human cytomegalovirus

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis

Volumn , Issue , 2007, Pages 1192-1210

  Griffiths, Paul D ^a   Boeckh, Michael ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929269449     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545313.067     Document Type: Chapter

References (108)

1. Adler, H., Messerle, M., and Koszinowski, U. H. (2003). Cloning of herpesviral genomes as bacterial artificial chromosomes. Rev. Med. Virol., 13(2), 111-121.
2. Balfour, H. H., Jr., Chace, B. A., Stapleton, J. T., Simmons, R. L., and Fryd, D. S. (1989). A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med., 320(21), 1381-1387.
3. Betts, R. F., Freeman, R. B., Douglas, R. G., Jr., and Talley, T. E. (1977). Clinical manifestations of renal allograft derived pri-mary cytomegalovirus infection. Am. J. Dis. Child., 131(7), 759-763.
4. Boeckh, M. and Nichols, W. G. (2003). Immunosuppressive effects of beta-herpesviruses. Herpes, 10(1), 12-16.
5. Boeckh, M. and Nichols, W. G. (2004). The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antivi-ral prophylaxis and preemptive therapy. Blood, 103(6), 2003-2008.
6. Boeckh, M., Gooley, T. A., Myerson, D., Cunningham, T., Schoch, G., and Bowden, R. A. (1996). Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood, 88(10), 4063-4071.
7. Boeckh, M., Bowden, R. A., Storer, B. et al. (2001). Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transpl., 7(6), 343-351.
8. Boivin, G., Gilbert, C., Gaudreau, A., Greenfield, I., Sudlow, R., and Roberts, N. A. (2001). Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis., 184(12), 1598-1602.
9. Bowden, R. A., Fisher, L. D., Rogers, K., Cays, M., and Meyers, J. D. (1991). Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J. Infect. Dis., 164(3), 483-487.
10. Bowen, E. F., Wilson, P., Cope, A. et al. (1996). Cytomegalovirus retinitis in AIDS patients: Influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS, 10(13), 1515-1520.
11. Bowen, E. F., Emery, V. C., Wilson, P. et al. (1998). Cytomegalovirus polymerase chain reaction viraemia in patients receiving gan-ciclovir maintenance therapy for retinitis. AIDS, 12(6), 605-611.
12. Cheeseman, S. H., Rubin, R. H., Stewart, J. A. et al. (1979). Con-trolled clinical trial of prophylactic human-leukocyte inter-feron in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N. Engl. J. Med., 300(24), 1345-1349.
13. Chou, S., Miner, R. C., and Drew, W. L. (2000). A deletion mutation in regionV of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J. Infect. Dis., 182(6), 1765-1768.
14. Chou, S., Waldemer, R. H., Senters, A. E. et al. (2002). Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis., 185(2), 162-169.
15. Chou, S., Lurain, N. S., Thompson, K. D., Miner, R. C., and Drew, W. L. (2003). Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis., 188(1), 32-39.
16. Cope, A. V., Sabin, C., Burroughs, A., Rolles, K., Griffiths, P. D., and Emery, V. C. (1997a). Interrelationships among quan-tity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methyl-prednisolone as risk factors for HCMV disease following liver transplantation. J. Infect. Dis., 176(6), 1484-1490.
17. Cope, A. V., Sweny, P., Sabin, C., Rees, L., Griffiths, P. D., and Emery, V. C.(1997b). Quantity of cytomegalovirus viruria is a majorrisk factor for cytomegalovirus disease after renal transplantation. J. Med. Virol., 52(2), 200-205.
18. Crippa, F., Corey, L., Chuang, E. L., Sale, G., and Boeckh M. (2001). Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell trans-plantation. Clin. Infect. Dis., 32(2), 214-219.
19. Deayton, J., Mocroft, A., Wilson, P., Emery, V. C., Johnson, M. A., and Griffiths, P. D. (1999). Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS, 13(10), 1203-1206.
20. Deayton, J. R., Sabin, C., Johnson, M. A., Emery, V. C., Wilson, P., and Griffiths, P. D. (2004). Cytomegalovirus viraemia remains an important risk factor for disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet, 363(9427), 2116-2121.
21. De Clercq, E., Naesens, L., De Bolle, L., Schols, D, Zhang, Y., and Neyts, J. (2001). Antiviral agents active against human her-pesviruses HHV-6, HHV-7 and HHV-8. Rev. Med. Virol., 11(6), 381-395.
22. Drew, W. L., Miner, R. C., Busch, D. F. et al. (1991). Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis., 163(4), 716-719.
23. Einsele, H., Ehninger, G., Hebart, H. et al. (1995). Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood, 86(7), 2815-2820.
24. Emery, V. C. and Griffiths, P. D. (2000). Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl Acad. Sci. USA, 97(14), 8039-8044.
25. Emery, V. C., Cope, A. V., Bowen, E. F., Gor, D., and Griffiths, P. D. (1999). The dynamics of human cytomegalovirus replication in vivo. J. Exp. Med., 190(2), 177-182.
26. Emery, V. C., Sabin, C. A., Cope, A. V., Gor, D., Hassan-Walker, A. F., and Griffiths, P. D. (2000). Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet, 355(9220), 2032-2036.
27. Emery, V. C., Hassan-Walker, A. F., Burroughs, A. K., and Griffiths, P. D. (2002). Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and-experienced immunocompro-mised hosts. J. Infect. Dis., 185(12), 1723-1728.
28. Erice, A., Chou, S., Biron, K. K., Stanat, S. C., Balfour, H. H., Jr., and Jordan, M. C. (1989). Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med., 320(5), 289-293.
29. Falagas, M. E., Snydman, D. R., Griffith, J., and Werner, B. G. (1996). Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin. Infect. Dis., 23(3), 468-474.
30. Feinberg, J. E., Hurwitz, S., Cooper, D. et al. (1998). A ran-domized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Pro-phylaxis Study Group. J. Infect. Dis., 177(1), 48-56.
31. Fletcher, C. V., Englund, J. A., Edelman, C. K., Gross, C. R., Dunn, D. L., and Balfour, H.H.(1991). Jr.Pharmacologicbasisforhigh-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob. Agents Chemother., 35(5), 938-943.
32. Furman, P. A., St. Clair, M. H., and Spector, T. (1984). Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J. Biol. Chem., 259(15), 9575-9579.
33. Gane, E., Saliba, F., Valdecasas, G. J. et al. (1997). Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet, 350(9093), 1729-1733.
34. Gerna, G., Baldanti, F., Lilleri, D. et al. (2003a). Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: A prospective, randomized, controlled, open-label trial. Transplantation, 75(7), 1012-1019.
35. Gerna, G., Lilleri, D., Baldanti, F. et al. (2003b). Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: A prospective, randomized, open-label trial. Blood, 101(12), 5053-5060.
36. Gilbert, C. and Boivin, G. (2003). Discordant phenotypes and geno-types of cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. AIDS, 17(3), 337-341.
37. Gleaves, C. A., Smith, T. F., Shuster, E. A., and Pearson, G. R. (1984). Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J. Clin. Microbiol., 19(6), 917-919.
38. Goodrich, J. M., Mori, M., Gleaves, C. A. et al. (1991). Early treatment with ganciclovir to prevent cytomegalovirus disease after allo-geneic bone marrow transplantation. N. Engl. J. Med., 325(23), 1601-1607.
39. Goodrich, J. M., Bowden, R. A., Fisher, L., Keller, C., Schoch, G., and Meyers, J. D. (1993). Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med., 118(3), 173-178.
40. Gor, D., Sabin, C., Prentice, H. G. et al. (1998). Longitudinalfluctuations in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transpl., 21(6), 597-605.
41. Grattan, M. T., Moreno-Cabral, C. E., Starnes, V. A., Oyer, P. E., Stinson, E. B., and Shumway, N. E. (1989). Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J. Am. Med. Assoc., 261(24), 3561-3566.
42. Griffiths, P. D. (2002). The 2001 Garrod lecture. The treatment of cytomegalovirus infection. J. Antimicrob. Chemother., 49(2), 243-253.
43. Griffiths, P. D. and McLaughlin, J. E. (1997). Cytomegalovirus. Infect. Centr. Nerv. Syst., 107-115.
44. Griffiths, P. D., Panjwani, D. D., Stirk, P. R. et al. (1984). Rapid diag-nosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fiuorescent foci. Lancet, 2(8414), 1242-1245.
45. Griffiths, P. D., Feinberg, J. E., Fry, J. et al. (1998). The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Tri-als Group Protocol 204/Glaxo Wellcome 123-014 Interna-tional CMV Prophylaxis Study Group. J. Infect. Dis., 177(1), 57-64.
46. Grundy, J. E., Shanley, J. D., and Griffiths, P. D. (1987). Is cytomegalovirus interstitial pneumonitis in transplant recipi-ents an immunopathological condition? Lancet, 2(8566), 996-999.
47. Grundy, J. E., Lui, S. F., Super, M. et al. (1988). Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recip-ient virus. Lancet, 2(8603), 132-135.
48. Guetta, E., Guetta, V., Shibutani, T., and Epstein, S. E. (1997). Mono-cytes harboring cytomegalovirus: Interactions with endothe-lial cells, smooth muscle cells, and oxidized low-density lipoprotein. Possible mechanisms for activating virus deliv-ered by monocytes to sites of vascular injury. Circ. Res., 81(1), 8-16.
49. Hassan-Walker, A. F., Kidd, I. M., Sabin, C., Sweny, P., Griffiths, P. D., and Emery, V. C. (1999). Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J. Med. Virol., 58(2), 182-187.
50. Hibberd, P. L., Tolkoff-Rubin, N. E., Conti, D. et al. (1995). Preemp-tive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recip-ients. A randomized controlled trial. Ann. Intern. Med., 123(1), 18-26.
51. Hirsch, M. S., Schooley, R. T., Cosimi, A. B., et al. (1983). Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N. Engl. J. Med., 308(25), 1489-1493.
52. Hu, H., Jabs, D. A., Forman, M. S. et al. (2002). Compari-son of cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with acquired immunodefi-ciency syndrome and CMV retinitis. J. Infect. Dis., 185(7), 861-867.
53. Humar, A., Lipton, J., Welsh, S., Moussa, G., Messner, H., and Maz-zulli, T. (2001). A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone mar-row and peripheral blood stem cell transplant recipients. Bone Marrow Transpl., 28(5), 485-490.
54. Jacobson, M. A. (1997). Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med., 337(2), 105-114.
55. Jacobson, M. A., Zegans, M., Pavan, P. R. et al. (1997). Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet, 349(9063), 1443-1445.
56. Karavellas, M. P., Plummer, D. J., Macdonald, J. C. et al. (1999). Inci-dence of immune recovery vitritis in cytomegalovirus retini-tis patients following institution of successful highly active antiretroviral therapy. J. Infect. Dis., 179(3), 697-700.
57. Kawaguchi, Y. and Kato, K. (2003). Protein kinases conserved in her-pesviruses potentially share a function mimicking the cellular protein kinase cdc2. Rev. Med. Virol., 13(5), 331-340.
58. Kidd, I. M., Fox, J. C., Pillay, D., Charman, H., Griffiths, P. D., and Emery, V. C. (1993). Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplanta-tion, 56(4), 867-871.
59. Kimberlin, D. W., Lin, C. Y., Sanchez, P. J. et al. (2003). Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. J. Pediatr., 143(1), 16-25.
60. Krosky, P. M., Baek, M. C., and Coen, D. M. (2003). The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol., 77(2), 905-914.
61. Lemstrom, K., Sihvola, R., Bruggeman, C., Hayry, P., and Koskinen, P. (1997). Cytomegalovirus infection-enhanced cardiac allo-graft vasculopathyis abolished byDHPGprophylaxis in the rat. Circulation, 95(12), 2614-2616.
62. Limaye, A. P., Corey, L., Koelle, D. M., Davis, C. L., and Boeckh, M. (2000). Emergence of ganciclovir-resistantcytomegalovirus disease among recipients of solid-organ transplants. Lancet, 356(9230), 645-649.
63. Lin, D. Y., Warren, J. F., Lazzeroni, L. C., Wolitz, R. A., and Mansour, S. E. (2002). Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV infected patients: Natural history and clinical predictors. Retina, 22(3), 268-277.
64. Liu, W., Shum, C., Martin, D. F., Kuppermann, B. D., Hall, A. J., and Margolis, T. P. (2000). Prevalence of antiviral drug resistance in untreated patients with cytomegalovirus retinitis. J. Infect. Dis., 182(4), 1234-1238.
65. Ljungman, P., Engelhard, D., Link, H. et al. (1992). Treatment of interstitial pneumonitis due to cytomegalovirus with ganci-clovir and intravenous immune globulin: Experience of Euro-pean Bone Marrow Transplant Group. Clin. Infect. Dis., 14(4), 831-835.
66. Ljungman, P., Griffiths, P., and Paya, C. (2002). Definitions of cytomegalovirusinfectionanddiseaseintransplant recipients. Clin. Infect. Dis., 34(8), 1094-1097.
67. Lowance, D., Neumayer, H. H., Legendre, C. M. et al. (1999). Valacy-clovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med., 340(19), 1462-1470.
68. Lui, S. F., Ali, A. A., Grundy, J. E., Fernando, O. N., Griffiths, P. D., and Sweny, P. (1992). Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol. Dial. Transpl., 7(12), 1230-1237.
69. Macdonald, P. S., Keogh, A. M., Marshman, D. et al. (1995). Adouble-blind placebo-controlled trial of low-dose ganciclovir to pre-vent cytomegalovirus disease after heart transplantation. J. Heart Lung Transpl., 14(1 Pt 1), 32-38.
70. Mar, E. C., Huang, E. S., Cheng, Y. C., and Chiou, J. F. (1985). Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J. Virol., 53(3), 776-780.
71. Martin, D. F., Sierra-Madero, J., Walmsley, S. et al. (2002). A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med., 346(15), 1119-1126.
72. Mattes, F. M., McLaughlin, J. E., Emery, V. C., Clark, D. A., and Griffiths, P. D. (2000). Histopathological detection of owl's eye inclusions is still specific for cytomegalovirus in the era of human herpesviruses 6 and 7. J. Clin. Pathol., 53(8), 612-614.
73. Mattes, F. M., Hainsworth, E. G., Geretti, A. M., et al. (2004). A ran-domized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J. Infect. Dis., 189(8), 1355-1361.
74. Merigan, T. C., Renlund, D. G., Keay, S. et al. (1992). A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N. Engl. J. Med., 326(18), 1182-1186.
75. Metselaar, H. J., Rothbarth, P. H., Brouwer, R. M., Wenting, G. J., Jeekel, J., and Weimar, W. (1989). Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation, 48(2), 264-266.
76. Meyers, J. D., Ljungman, P., and Fisher, L. D. (1990). Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: Importance of cytomegalovirus viremia. J. Infect. Dis., 162(2), 373-380.
77. Nichols, W. G., Corey, L., Gooley, T., Davis, C., and Boeckh, M. (2002). High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J. Infect. Dis., 185(3), 273-282.
78. Paya, C., Humar, A., Dominguez, E. et al. (2004). Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transpl., 4(4), 611-620.
79. Paya, C. V., Wilson, J. A., Espy, M. J., et al. (2002). Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: A randomized, placebo-controlled trial. J. Infect. Dis., 185(7), 854-860.
80. Prentice, H. G., Gluckman, E., Powles, R. L. et al. (1994). Impact of long-term acyclovir on cytomegalovirus infection and sur-vival after allogeneic bone marrow transplantation. European Acyclovir forCMV Prophylaxis Study Group. Lancet, 343(8900), 749-753.
81. Razonable, R. R., Brown, R. A., Wilson, J. et al. (2002). The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation, 73(6), 968-973.
82. Reed, E. C., Wolford, J. L., Kopecky, K. J. et al. (1990). Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone mar-row transplant patients. A randomized, placebo-controlled trial. Ann. Intern. Med., 112(7), 505-510.
83. Reinke, P., Fietze, E., Ode-Hakim, S. et al. (1994). Late-acute renal allograft rejection and symptomless cytomegalovirus infec-tion. Lancet, 344(8939-8940), 1737-1738.
84. Reusser, P., Einsele, H., Lee, J. et al. (2002). Randomized multicen-ter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell trans-plantation. Blood, 99(4), 1159-1164.
85. Rubin, R. H. (1991). Preemptive therapy in immunocompromised hosts. N. Engl. J. Med., 324(15), 1057-1059.
86. Safrin, S., Cherrington, J., and Jaffe, H. S. (1997). Clinical uses of cidofovir. Rev. Med. Virol., 7(3), 145-156.
87. Schmidt, G. M., Horak, D. A., Niland, J. C., Duncan, S. R., Forman, S. J., and Zaia, J. A.(1991). A randomized, controlled trialof pro-phylacticganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N. Engl. J. Med., 324(15), 1005-1011.
88. Shinkai, M. and Spector, S. A. (1995). Quantitation of human cytomegalovirus (HCMV) DNA in cerebrospinal fluid by com-petitive PCR in AIDS patients with different HCMV cen-tral nervous system diseases. Scand. J. Infect. Dis., 27(6), 559-561.
89. Singh, N. (2006). Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev. Med. Virol., 16(5), 281-287.
90. Snydman, D. R., Werner, B. G., Dougherty, N. N. et al. (1993). Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. The Boston Center for Liver Transplan-tation CMVIG Study Group. Ann. Intern. Med., 119(10), 984-991.
91. Snydman, D. R. (2006). The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev. Med. Virol. 16(5), 289-295.
92. Spector, S. A., Merrill, R., Wolf, D., and Dankner, W.M.(1992). Detec-tion of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J. Clin. Microbiol., 30(9), 2359-2365.
93. Spector, S. A., McKinley, G. F., Lalezari, J. P. et al. (1996). Oral ganci-clovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N. Engl. J. Med., 334(23), 1491-1497.
94. Spector, S. A., Wong, R., Hsia, K., Pilcher, M., and Stempien, M. J. (1998). Plasma cytomegalovirus (CMV) DNA load pre-dicts CMV disease and survival in AIDS patients. J. Clin. Invest., 101(2), 497-502.
95. Spector, S. A., Hsia, K., Crager, M., Pilcher, M., Cabral, S., and Stem-pien, M.J.(1999). Cytomegalovirus(CMV) DNA load is an inde-pendent predictor of CMV disease and survival in advanced AIDS. J. Virol., 73(8), 7027-7030.
96. Speir, E., Modali, R., Huang, E. S. et al. (1994). Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science, 265(5170), 391-394.
97. Speir, E., Shibutani, T., Yu, Z. X., Ferrans, V., and Epstein, S. E. (1996). Role of reactive oxygen intermediates in cytomegalovirus gene expression and in the response of human smooth muscle cells to viral infection. Circ. Res., 79(6), 1143-1152.
98. Stagno, S., Reynolds, D. W., Tsiantos, A., Fuccillo, D. A., Long, W., and Alford, C. A. (1975). Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections. J. Infect. Dis., 132(5), 568-577.
99. Streblow, D. N., Soderberg-Naucler, C., Vieira, J. et al. (1999). The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell, 99(5), 511-520.
100. Talarico, C. L., Burnette, T. C., Miller, W. H. et al. (1999). Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob. Agents Chemother., 43(8), 1941-1946.
101. The, T. H., van der, B. W., van den Berg, A. P., van der Giessen, M. et al. (1990). Cytomegalovirus antigenemia. Rev. Infect. Dis., 12 Suppl. 7, 734-744.
102. Valantine, H. A., Gao, S. Z., Menon, S. G. et al. (1999). Impact of prophylactic immediate posttransplant ganciclovir on devel-opment of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study. Circulation, 100(1), 61-66.
103. Wagner, J. A., Ross, H., Hunt, S. et al. (1995). Prophylactic gan-ciclovir treatment reduces fungal as well as cytomegalovirus infections after hearttransplantation. Transplantation, 60(12), 1473-1477.
104. Whitcup, S. M., Fortin, E., Lindblad, A. S. et al. (1999). Discontinua-tion of anticytomegalovirus therapy in patients with HIV infec-tion and cytomegalovirus retinitis. J. Am. Med. Assoc., 282(17), 1633-1637.
105. Winston, D. J. and Busuttil, R. W. (2004). Randomized con-trolled trial of sequential intravenous and oral ganci-clovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation, 77(2), 305-308.
106. Winston, D. J., Ho, W. G., Bartoni, K. et al. (1993). Ganciclovir pro-phylaxisofcytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-con-trolled double-blind trial. Ann. Intern. Med., 118(3), 179-184.
107. Winston, D. J., Wirin, D., Shaked, A., and Busuttil, R. W. (1995). Ran-domised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet, 346(8967), 69-74.
108. Winston, D. J., Yeager, A. M., Chandrasekar, P. H., Snydman, D. R., Petersen, F. B., and Territo, M. C. (2003). Random-ized comparison of oral valacyclovir and intravenous gan-ciclovir for prevention of cytomegalovirus disease after allo-geneic bone marrow transplantation. Clin. Infect. Dis., 36(6), 749-758.